Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1
NCT06225427
Gilteritinib for the Treatment of ALK NSCLC
- NCT06225427 ↗
- Recruiting
- University of Michigan Rogel Cancer Center
- Focused size, estimated: 1–150 verified statements
We haven't built an HCP commentary report on NCT06225427 (gilteritinib in ALK-positive stage IV non-small cell lung cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT06225427 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X |
The trial
ClinicalTrials.gov- Official title
- Phase I Study of Gilteritinib for ALK Positive Non-Small Cell Lung Cancer
- Phase
- Phase 1
- Status
- Recruiting
- Conditions
- Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8
- Interventions
- Biopsy; Biospecimen Collection; Computed Tomography; Echocardiography; Gilteritinib; Magnetic Resonance Imaging; Questionnaire Administration
- Arms
- Treatment (gilteritinib) · Experimental
- Enrollment
- 30 (estimated)
- Primary outcomes
- Incidence of adverse events
- Dose-limiting toxicities (DLT)
- Sponsor
- University of Michigan Rogel Cancer Center
- Start
- Jul 25, 2024
- Primary completion
- May 2027 (estimated)
- Results posted
- No
- Registry record
- NCT06225427 · updated Jun 26, 2026